Ziprasidone

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Posttraumatic Stress Disorder

Conditions

Posttraumatic Stress Disorder, Post-Traumatic Stress Disorder, PTSD

Trial Timeline

Dec 1, 2002 → Apr 1, 2005

NCT ID

NCT00208208

About Ziprasidone

Ziprasidone is a approved stage product being developed by Pfizer for Posttraumatic Stress Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00208208. Target conditions include Posttraumatic Stress Disorder, Post-Traumatic Stress Disorder, PTSD.

What happened to similar drugs?

2 of 3 similar drugs in Posttraumatic Stress Disorder were approved

Approved (2) Terminated (1) Active (1)

✅Placebo + sertralineJohnson & JohnsonApproved

✅Adjunctive asenapineMerckApproved

🔄Duloxetine hydrochlorideEli LillyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01157559	Approved	Completed	—	May 1, 2010	First Episode Psychosis
NCT02935998	Approved	UNKNOWN	Oct 1, 2016	Dec 1, 2017	Schizophrenia
NCT01293825	Approved	Completed	Jan 1, 2011	Aug 1, 2012	Medication Adherence
NCT01198353	Approved	Completed	Sep 1, 2010	Dec 1, 2013	Schizophrenia
NCT00579670	Pre-clinical	Completed	Oct 1, 2007	Apr 1, 2009	Schizophrenia
NCT00454883	Pre-clinical	Completed	Apr 1, 2007	Dec 1, 2007	Affective Psychosis, Bipolar
NCT00406315	Approved	Completed	Nov 1, 2006	Mar 1, 2009	Schizophrenia
NCT00421954	Phase 3	Completed	May 1, 2006	May 1, 2009	Schizophreniform Disorder
NCT01053429	Pre-clinical	Completed	Jun 1, 2005	Feb 1, 2010	Bipolar Disorder
NCT00458211	Approved	Completed	May 1, 2005	Apr 1, 2008	Schizophrenia
NCT00237666	Approved	Completed	Feb 1, 2005	Feb 1, 2008	Bipolar II Disorder
NCT00351000	Approved	Completed	Jan 1, 2005	Mar 1, 2007	Schizophrenia
NCT00137020	Approved	Completed	Nov 1, 2004	Apr 1, 2006	Schizophrenia
NCT00645229	Phase 3	Terminated	Sep 1, 2004	Mar 1, 2005	Schizophrenia
NCT00649064	Approved	Completed	Dec 1, 2003	Sep 1, 2004	Schizoaffective Disorder
NCT00650429	Approved	Completed	Oct 1, 2003	May 1, 2005	Schizophrenia
NCT00395031	Phase 2/3	Completed	Sep 1, 2003	Jan 1, 2010	Schizophrenia
NCT00645320	Approved	Completed	Aug 1, 2003	Aug 1, 2004	Pyschotic Disorders
NCT00644800	Approved	Completed	Jul 1, 2003	May 1, 2004	Schizophrenia
NCT00143351	Phase 3	Completed	Jun 1, 2003	Sep 1, 2005	Schizophrenia

Competing Products

8 competing products in Posttraumatic Stress Disorder

See all competitors

Product	Company	Stage	Hype Score
Duloxetine hydrochloride	Eli Lilly	Phase 3	36
Nepicastat + Placebo	Johnson & Johnson	Phase 2	35
Placebo + sertraline	Johnson & Johnson	Approved	35
Adjunctive asenapine	Merck	Approved	43
sertraline (Zoloft)	Pfizer	Pre-clinical	26
Methylphenidate Hydrochloride 20 mg + Placebo Capsule + Galantamine 12 mg	Brain Biotech	Phase 2	17
High THC/Low CBD Cannabis + High THC/High CBD Cannabis + Low THC/Low CBD Cannabis	Tilray	Phase 2	29
Riluzole	Brain Biotech	Phase 1	19